ArticleVeterinary and animal science2023
Case report: Amniotic fluid-derived mesenchymal stem cell treatment in a dog with a spinal cord injury.
Article in Veterinary and animal science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Current Advances in Mesenchymal Stem Cell Therapies Applied to Wounds and Skin, Eye, and Neuromuscular Diseases in Companion Animals.Animals : an open access journal from MDPI · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal Cord Injury (SCI) refers to complete or incomplete damage to the spinal cord, which comprises the central nervous system. SCI in dogs, like humans, is mostly caused by external trauma, and the degree of impact is dependent on the location of the injury in the spine. Stem cell therapy is a promising avenue for SCI research. In this report, we investigate the therapeutic potential of amniotic fluid-derived mesenchymal stem cells (AF-MSCs) in dogs with spinal cord injuries. A 2-year-old male beagle dog presented with sensory and motor incomplete symptoms resulting in an inability to control the legs, hips, and genitourinary system due to an injury in the lumbar region of the spinal cord. In addition to the administration of surgical decompression, AF-MSCs were directly injected into the damaged spinal tissue. Approximately 15-16 weeks after stem cell transplantation, the dog's hind limb movement improved, and spinal cord regeneration was confirmed through magnetic resonance imaging (MRI). Eventually, the dog was able to walk independently, although not perfectly. In conclusion, AF-MSC-based stem cell transplantation may be beneficial for SCIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.